Gold prices edge higher on raised Fed rate cut hopes
Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (NASDAQ:AKRO), recently sold shares of the company’s common stock totaling approximately $1.25 million. The stock has shown remarkable strength with a 78.4% gain over the past six months, reaching a current market capitalization of $3.65 billion. The transactions occurred on March 10, 2025, under a pre-established Rule 10b5-1 trading plan. Cheng sold 28,784 shares at a weighted-average price of $41.746, with individual transaction prices ranging from $41.22 to $42.21. Additionally, he sold another 1,216 shares at a weighted-average price of $42.313, with prices ranging from $42.226 to $42.500. Following these sales, Cheng holds 656,062 shares directly. The stock, which typically moves counter to broader market trends with a beta of -0.2, currently trades at $45.85. InvestingPro analysis reveals strong analyst support, with targets ranging from $60 to $109 per share. Get deeper insights into insider trading patterns and 12 additional ProTips with an InvestingPro subscription.
In other recent news, Akero Therapeutics has seen several analysts revise their price targets upward following promising trial results for its leading drug candidate, efruxifermin (EFX). Citi analysts have raised their target to $80, citing the significant milestone achieved in the 96-week SYMMETRY study for patients with cirrhosis caused by metabolic-associated steatohepatitis (MASH F4C). Jefferies also increased their target to $75, highlighting Akero’s potential to capture a substantial market opportunity in the NASH sector. Canaccord Genuity adjusted their target to $73, expressing optimism over the SYMMETRY study’s positive data on fibrosis improvement. H.C. Wainwright raised their target to $72, based on a revised net present value model for EFX’s market potential in MASH and F2/F3 fibrosis. Analysts from H.C. Wainwright and Citi both maintain a Buy rating, reflecting confidence in Akero’s future performance. The recent developments underscore the potential for Akero’s EFX to become a foundational treatment in a challenging patient demographic. The anticipation of market growth and possible FDA accelerated approval are key factors driving these positive outlooks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.